Earlier studies indicated that targeting the CHK1/CHK2 axis with a non-selective dual inhibitor was able to sensitise CD133+ glioma CSCs to radiotherapy and reduce their in vivo tumorigenicity [145,146,152]. The gene discussed is PROM1; the disease is central nervous system cancer.